مباشر
FierceBiotechResmed snaps up Noctrix Health in $340M sleep tech dealEndpoints NewsJ&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS fieldFierceBiotechJ&J makes $1B upfront bet on emerging DAC space by netting Firefly BioEndpoints NewsGSK inks multi-target pact with Engitix; Sangamo considers strategic optionsEndpoints NewsTango plans Phase 3 pancreatic cancer study after combo successEndpoints NewsComing SoonEndpoints NewsBiopharma's top-paid CEOs of 2025: 25 making $25M+Endpoints NewsCavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugsFierceBiotechBiopharma moves to reduce development risk earlier than everFierceBiotechIncyte inks $2B deal to add Star unit to late-phase constellation and challenge TakedaEndpoints News#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shotFierceBiotechWhy Execution Excellence Now Defines Biopharma Winners
Endpoints News ١٨ ديسمبر ٢٠٢٥

Subcutaneous Rybrevant; Kalaris shares nAMD data; Pyxis disappoints

Subcutaneous Rybrevant; Kalaris shares nAMD data; Pyxis disappoints

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.